Professional Documents
Culture Documents
Long-Term Efficacy of House Dust Mite Immunotherapy in Bronchial Asthma: A 15-Year Follow-Up Study
Long-Term Efficacy of House Dust Mite Immunotherapy in Bronchial Asthma: A 15-Year Follow-Up Study
Long-Term Efficacy of House Dust Mite Immunotherapy in Bronchial Asthma: A 15-Year Follow-Up Study
2005;54:443-449
ORIGINAL ARTICLE
ABSTRACT
Background: Specific immunotherapy for bronchial asthma has been documented to be efficacious in several
studies ; however, it is not known whether this efficacy is sustained for several years after cessation of immu-
notherapy. The aim of this study is to determine the efficacy of house dust mite immunotherapy over a 15-year
period.
Methods: This study is an open, parallel, comparative trial in which 31 patients were administered immuno-
therapy for 5 years and then followed-up for a further 10 years. Their global symptom scores and FEV1 values
were compared with another group of 38 patients who refused immunotherapy.
Results: The use of immunotherapy resulted in a statistically significant improvement in both global symptom
scores and FEV1 in patients receiving immunotherapy when compared with those in the control group who did
not receive immunotherapy. This improvement was sustained for at least 10 years after cessation of immuno-
therapy.
Conclusions: The benefits of house dust mite immunotherapy are significant and sustained, a decade after
its discontinuation.
KEY WORDS
allergy, benefits, bronchial asthma, house dust mite, immunotherapy
INTRODUCTION METHODS
Specific immunotherapy (SIT) has been used in the INVESTIGATIONS
management of allergic diseases since 1911. 1 Several 85 selected patients with BA (of more than 512 newly
studies have clearly documented the clinical efficacy detected BA cases who attended the clinic during the
of SIT in house dust mite allergy , yet this mode of year 1986) were subjected to a detailed history and
therapy remains controversial , 2 especially in bron- physical examination. Each patient underwent the fol-
chial asthma ( BA ) despite the fact that 3 meta- lowing investigations
analyses have proven the beneficial effects in this ( 1 ) Estimation of serum IgE levels ( radio-
condition.3-5 immunoassay)
A very important question to be answered is (2) Skin prick tests (SPT) with a battery of com-
whether the effects of SIT are long lasting, particu- mon Indian allergens (ALCIT India Pvt. Ltd., Delhi,
larly after it has been discontinued. If the answer is India)6
yes, it would make SIT an attractive, disease modify- (3) Specific IgE levels (RAST) to the house dust
ing, treatment modality for allergic diseases such as mite D. farinae.
asthma and! or rhinitis. (4) Spirometry
This study is a prospective , open , parallel , com- (5) Peak nasal inspiratory flow rates (PNFIR) using
parative trial of SIT versus a control group of patients a Youltens nasal flow meter (Clement Clark Interna-
who did not receive SIT. tional, London, UK)
16 SIT
Control
14
12
10
Mean % Change in FEV1
-2
-4
-6 Mar 87 Mar 88 Mar 89 Mar 90 Mar 91 Mar 92 Mar 93 Mar 94 Mar 95 Mar 96 Mar 97 Mar 98 Mar 99 Mar 00 Mar 01
Time (Mar 1987 Dec 2001)
Fi
g.1Per cent
agechangeandvar
iat
ioni
nFEV1 i
nthecont
rol(
C)andspeci
fi
cimmunot
her
apy(
SIT)
gr
oupsoveraperiodof15year
s
mately 40 bioequivalent allergy units (BAU !ml ) to the beginning of the study, compare it with the status
start with 9 a maximum of 8000 BAU !ml during the on evaluation day and then decide on the current
maintenance phase , which would be designated as symptom score.
high dose All the instructions provided by the
manufacturer (Alcit India Pvt. Ltd.) were carefully fol- Spirometry
lowed. Side effects of SIT (local and systemic) if any, FEV 1 values obtained through spirometry were
were observed and carefully recorded at each consul- noted and the percentage change in FEV1 (PCFEV1)
tation. Between January 1, 1987 and December 31, was calculated at each visit, taking the FEV1 at the
2001, while the study was ongoing, symptom scores beginning of the study as the baseline value . Al-
and FEV1 of each patient were recorded once every 3 though this was an open trial, in order to eliminate
months on the first day of March, June, September bias, the clinic secretaries recorded symptom scores
and December and the clinic physician conducted spirometry. Clinic
secretaries were strictly instructed not to discuss
Symptom Scores with patients their mode of treatment. Also, patients
Symptom scores were assessed on a visual analogue from both groups were assigned to different days for
scale (VAS) from 0 to 10, where0indicated wors- clinic visits (even dates for the SIT group and odd
ening or no improvement and 10 indicated maximal dates for the control group) so as to ensure that no
improvement. While assessing symptom scores, pa- patients from one group would meet patients from
tients were instructed to make a global evaluation, in- the other group during the course of this study
cluding frequency and severity of symptoms , pres-
ence of other complaints such as cough and phlegm Rescue Medication Records
and improvement in quality of life Each patient was instructed to keep a careful record
Since symptom scores were evaluated for a lengthy of the number of doses of rescue salbutamol used.
15 year period, the possibility of patients forgetting Patients were asked to report back to the clinic if they
their initial global symptom severity and intensity was had any uncontrolled symptoms or clarifications. Pa-
kept in mind . Consequently during the symptom tients not responding to salbutamol MDI were asked
score evaluation period every attempt was made to to report to the clinic immediately and were pre-
jog the patients memory, re-live symptom severity at scribed a short course of oral prednisolone , begin-
10 STI
Control
9
7
Changes in symptom scores
-1
Mar 87 Mar 88 Mar 89 Mar 90 Mar 91 Mar 92 Mar 93 Mar 94 Mar 95 Mar 96 Mar 97 Mar 98 Mar 99 Mar 00 Mar 01
Time (Mar 1987 Dec 2001)
Fig.2Per
cent
agechangeandvari
ati
onins
ympt
om scor
esi
nthec
ont
rol(
C)andspeci
fi
cimmunot
her
-
apy(SI
T)gr
oupsoveraper
iodof15years
8
Mean Symptom Scores
0
-3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13
Mean % Change in FEV1
Fi
g.3Cor r
elat
i
onbet
weenmean% changei
nFEV1andmeansy
mpt
om s
cor
es
i
nthespeci
f
icimmunot
her
apy(
SIT)gr
oup
7
Pearsons Corr = 0.58
P < 0.01
6
0
-3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Mean % Change in FEV1
Fi
g.4Cor r
elati
onbet
weenmean% c
hangei
nFEV1 andmeans
ympt
om scor
es
i
nthecont
rolgroup
ning with 30 mg per day and tapered off within 3 asthma Control group patients had FEV1.0 ranging
weeks. from 68% to 76% of predicted normal values (mean-
71%) while those in the SIT group had FEV1.0 rang-
Skin Prick Tests ing from 66% to 70% (mean-70%)
SPT with D. farinae was repeated in all 85 patients be- The baseline data in this study revealed that the
fore the beginning of the study (December 1986), on SIT and Control groups were well matched with re-
discontinuation of SIT (January 1992) and on comple- gard to age, sex, disease period, total serum IgE lev-
tion of the study (January 2002) els and FEV1.0 (p< 0.05). This close match occurred
despite proper randomization and without any at-
Statistical Analysis tempt at stratification
Analysis of the correlation coefficient was calculated The results obtained from this study are shown in
using Pearsons test. The Mann Whitney test and Wil- Figures 14.
coxon Rank Sum test were used to compare the Both the PCFEV1 and the symptom scores were
symptom scores. PCFEV1 and SPT wheal sizes in the evaluated for each time point over a period of 15
two groups with p values < 0.05 were considered sta- years for both SIT and control group. Data were ex-
tistically significant. Area under the curve (AUC) was pressed as means + !- standard deviation (SD). Pa-
used to compare the overall effect of SIT with the tients receiving SIT showed less variability in SD
control group over the entire duration of the 15 year whereas patients in the control group showed a large
period. The SPSS statistical package was used to pre- variation over the 15-year period (Fig. 2).
dict the maximum possible period of benefit obtained Patients in the control group showed wide devia-
with SIT tions in mean symptom scores (range 2.60 to 6.21 )
and in PCFEV1 (varying up to 7%) during the study
RESULTS period. However, the SIT group showed a marked im-
Data obtained from this study showed that patients in provement through December 1987, a steady in-
the control group suffered from their disease for 1 to crease until December 1993, followed by a gradual
6 years (mean duration-2 years 7 months) whereas decline until December 2001 (Fig. 2)
those in the SIT group suffered for 1 to 7 years (mean Pearson correlations between mean PCFEV1 and
duration-3 years 5 months) mean symptom scores (Figs. 3, 4) showeda highly
Total serum IgE levels were in the range of 426 to significant correlationin the SIT group ( r = 0.87, p
978 IU!ml. (mean-581 IU!ml.) in the control group < 0.01) anda significant correlationin the control
and 488 to 1007 IU! ml (mean - 602 IU! ml.) in the SIT group ( r = 0.58, p < 0.01)
group The Mann-Whitney Test was performed for symp-
Based on the International Consensus Report, 7 all tom scores. The null hypotheses of no difference be-
69 cases were classified as moderately severe tween patients receiving SIT and control group was
Tabl
e 1 AREAUNDERTHE CURVE(
AUC)
Par
amet
er Group 1987t o1991 1992t o2001 1987t o2001 pval
ues
SIT 159.72 409.38 569.10
% changei
nFEV1.
0(PCFEV1) p<0.
05
Cont
rol 122.78 155.33 278.11
SIT 139.85 277.73 417.58
Sy
mpt
om Scor
es p<0.
05
Cont
rol 101.43 145.78 247.21
rejected . There was a statistically significant differ- tained for the rest of the study due to inaccurate re-
ence between the two groups ( p < 0.01) with statisti- cording of MDI usage by patients in both groups
cally significant higher symptom scores in the SIT None of the 31 patients in the SIT group needed
group prednisolone during the 15-year study period. How-
Area under the curve ( AUC ) was estimated by ever, there were a total of 347 occasions when predni-
means of linear interpolation using the trapezoidal solone was administered to patients from the control
rule (EquivTest, version 2.0, Solutions Ltd., Republic group ; thus on an average each control group pa-
of Ireland). AUC was calculated for both PCFEV1 and tient required prednisolone 9 times during the study
symptom scores in both groups for the entire 15-year
period (1987 to 2001) and also separately for the pe- DISCUSSION
riod during which SIT was administered ( 1987 to The end points used in this study, viz. PCFEV1 and
1991 ) and the follow-up period ( 1992 to 2001 )(Ta- symptom scores are accepted as two of the most con-
ble 1).For all 3 periods, the AUC analysis concluded venient methods of monitoring the clinical efficacy of
that the AUC is significantly higher for the SIT group SIT. Bronchial hyper reactivity (BHR) was not con-
for both PCFEV1 and symptom scores ( p < 0.05) sidered as a parameter in this study since it has
The two sample Wilcoxon Rank Sum Test and con- yielded conflicting results in patients undergoing SIT.
fidence intervals ( CI ) for symptom scores and Of the eight studies measuring BHR before and after
PCFEV1 for March 1987 when compared with De- SIT, only one showed a decrease in BHR, but the re-
cember 2001 for the SIT group showed a statistically maining seven showed no change.9
significant difference ( p < 0.05 ) and significantly In addition there have been conflicting results with
higher scores for December 2001 regard to changes in skin reactivity following SIT. In
The data obtained from this study was applied to 13 out of 30 beneficial studies with SIT, four showed
the SPSS version 11.0 statistical package in an at- no change and nine demonstrated decreased skin
tempt to determine the maximum period of benefit test reactivity. 10 Furthermore, the present study con-
following cessation of SIT. Thecurve fit method firms that test reactivity is not a reliable end point for
predicted that symptom scores and PCFEV1 would studying the efficacy of SIT.
drop to zero in December 2014, which is after a dura- A number of studies have studied the efficacy of
tion of 28 years following initiation of the study (in SIT in asthma and !or rhinitis over periods varying
January 1987) from 1 to 6 years using house dust mite , tree and
The two-sample Wilcoxon Rank Sum Test was ap- grass pollen, fungi (Alternaria) and animal danders
plied to the skin prick test data which revealed no sig- (cat and! or dog).11-21 Only one study observed the ef-
nificant differences in wheal sizes when the 3 read- fects of SIT over a period of 14 years.22 However, that
ings (1986, 1992 and 2002) were compared to each study did not use any of the usual end points viz ,
other in both the SIT and control groups symptom scores, PCFEV1, SPT wheal size or bron-
Although side effects were not included in the chial hyperresponsiveness. Indeed, this same study
study plan, it is pertinent to note here that there were did not discuss the details of statistical analysis.
no systemic reactions in the SIT group. There were The present study has shown a statistically signifi-
however, 20 episodes of small local reactions (<4 cm cant improvement in end points in the SIT group ,
in diameter) at the site of injection, none of which re- which persisted for a decade after cessation of SIT
quired therapeutic intervention and using statistical projection would be expected to
The records maintained by patients revealed that last for approximately 13 years after completion of the
the control group inhaled a total of 61,400 puffs of sal- study (or for a total of 23 years following discontinu-
butamol (approximately 307 MDIs) during the first ation of SIT). This study concludes that contrary to all
year of this study as rescue medication. During the current skepticism , SIT indeed has a long lasting
same period the SIT group inhaled 8,600 puffs (or ap- beneficial role in BA. In sum, SIT could therefore be
proximately 43 MDIs). The difference therefore, be- considered a truly disease modifying drug (DMD)
tween the two groups with regards to rescue medica-
tion, is stark. However, no reliable data could be ob-